BioCryst Pharmaceuticals, Inc. announced that the company will present at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022, at 9:50 a.m. ET.
RESEARCH TRIANGLE PARK, N.C., March 03, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022, at 9:50 a.m. ET. The event will be held virtually.
The company also will present at the Barclays Global Healthcare Conference in Miami Beach, Florida on Wednesday, March 16, 2022, at 2:35 p.m. ET.
Links to a live audio webcast and replay of these presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States, the European Union, Japan, the United Kingdom and the United Arab Emirates. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection) has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at www.biocryst.com.
BCRXW
Investor Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
Media Contact:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com
